Sarcomas are classified based on morphology, IHC, and genetic characteristics and have different clinical behaviors (
3). The most common sign at the time of diagnosis is painless mass (
4). One of the effective factors in the relapse pattern and outcome is the site of disease (
2). About 40 - 50% of cases occur in the limbs, and 12% in the trunk (
3). Nevertheless, the tendency to early local relapse in retroperitoneal masses is higher (
2). The treatment of these patients, considering its rarity, should involve a multidisciplinary team (
3). The treatment modalities that are practical in STS include surgery, radiotherapy, and chemotherapy (
3). Sometimes and uncommonly, the risk of secondary carcinoma increases in STS patients even in the absence of genetic syndromes (
4). However, few patients with multiple soft tissue sarcoma have been reported; these cases are described as follows:
In the review by Lex et al. in examining the literature, they found 17 patients with multiple STS. The average time between the first and the second STS was around 2.3 years, but in 6 patients it existed synchronously (
4).
In the study by Grobmyer et al., among 5505 patients with STS from 1982 to 2003, 9 patients with multiple STS were found, which was metachronous in 7 patients; indeed, the prevalence of secondary STS in these patients was 0.2%, which is higher than the normal population (
5).
In the study by Merimsky et al., investigating 610 STS patients with bone sarcoma who had been treated in 1995 - 1999, 7.5% (n = 28) of patients had secondary malignancy before or after STS. In 14 patients, STS was the primary tumor, while the secondary tumors included STS (3patients), Renal cell carcinoma (RCC), breast, colon, melanoma, Non-small-cell carcinoma ( NSCLC), prostate, and papillary thyroid carcinoma ( PTC) (
6).
In 1980, Schiffman reported a synovial sarcoma case in the knee followed by epithelial sarcoma with lymphatic metastasis in the contralateral knee (
7).
In 2014, Scepanovic et al. reported a 19-year-old patient with bilateral shoulder Malignant fibrohistocytoma (MFH) as symmetric and metachronous with a 1.5-year interval (
8).
The most common method for tumor response evaluation after chemotherapy is response evaluation criteria in the solid tumor (RECIST) criteria but in soft tissue sarcoma, functional imaging is superior (
9). In our case, the size of the tumor did not change by chemotherapy but there was more than 50% necrosis which is representing tumor response.
3.1. Conclusions
According to previous reports and this report, multiple STS is rare; nevertheless, its probability, either synchronous or metachronous, should be considered during patient examine and follow-up. In the case of a secondary lesion, different histology is probable, and the patient should be biopsied and imaged.